Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial

Monique Aucoin; Kieran Cooley; Leena Anand; Melissa Furtado; Alex Canzonieri; Alexa Fine; Kathryn Fotinos; Ranjith Chandrasena; Larry J Klassen; Irvin Epstein; Wende Wood; Martin A Katzman

doi:10.1016/j.ctim.2017.09.011

Back

Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial

Journal article

Open access

Peer reviewed

Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial

Monique Aucoin, Kieran Cooley, Leena Anand, Melissa Furtado, Alex Canzonieri, Alexa Fine, Kathryn Fotinos, Ranjith Chandrasena, Larry J Klassen, Irvin Epstein, …

Complementary therapies in medicine, Vol.36, pp.38-45

02/2018

DOI: https://doi.org/10.1016/j.ctim.2017.09.011

PMID: 29458928

Files and links (2)

pdf

Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial428.69 kBDownload View

Published (Version of record)CC BY-NC-ND V4.0, Open Access

url

Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trialView

Published (Version of record)CC BY-NC-ND V4.0, Open

Metrics

49 File views/ downloads

10 Record Views

10 Times Cited - Web of Science

See more details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Abstract

Vitamin D

Depression

Clinical trial design

Obstacles

Background Many patients with depression fail to achieve remission after several consecutive treatments. Vitamin D deficiency is prevalent and new research suggests that it may have an impact on mood, primarily through an effect on neurotransmitters. Numerous observational studies suggest a relationship between low levels of vitamin D and increased incidence and severity of mood disorders. A small number of pilot studies have been undertaken but lack rigorous methodology required to draw conclusions about a clinical role for this nutrient in treatment resistant depression. Methods This study was designed as a randomized, double-blind, placebo controlled intervention study administering a weekly (bolus) dose of 28 000IU of Vitamin D3 or placebo to 125 patients with non-remitted depression adjunct to current antidepressant medication. Patients were followed weekly for eight weeks plus a one month follow up. Outcomes measured included depression severity, serum vitamin D levels and safety. Due to slow recruitment during the first season, amendments were made. These included extending the age range to 18–75 and removing the requirement for failing to respond to one pharmacologic antidepressant agent. The protocol was amended to reduce the burden on participants by changing the in-office visits to bi-weekly. Three additional tertiary psychiatric clinics were also added as trial sites. Results Over three recruitment period years (fall/winter), a total of 148 participants completed screening, 24 (16.2%) of whom qualified to participate in the study. Use of too many or no psychiatric medications, comorbid exclusionary psychiatric conditions, current use of a vitamin D supplement, and lack of participant compensation were the predominant reasons for ineligibility or unwillingness to participate. 9 participants were successfully enrolled in the study, 7 (77.8%) of whom completed the trial as per the protocol. After the third season, futility was declared based on inability to enroll participants. The sample size of enrolled participants (7/125, 5.6%) lacks power to conduct a full assessment of findings. Discussion High accessibility of vitamin D, as well as a growing lack of equipoise in patients and clinicians about the potential ubiquitous benefits of vitamin D for Canadians, not just for mood disorders, resulted in a large proportion of ineligible potential participants. Limited funding provided to studies on natural health products hampered recruitment. The labile and fluctuating nature of non-remitted depression as well as frequent co-morbid conditions creates additional challenges for conducting trials in this population. Future studies assessing vitamin D in depression should consider our experiences in design and conduct of research. Innovations in clinical trial design such as preference trials or accepting patients already using vitamin D but not achieving an optimal target value are potential solutions to some of these challenges.

Details

Title: Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial
Creators: Monique Aucoin - Canadian College of Naturopathic Medicine
Kieran Cooley - Canadian College of Naturopathic Medicine
Leena Anand - START Clinic
Melissa Furtado - START Clinic
Alex Canzonieri - START Clinic
Alexa Fine - START Clinic
Kathryn Fotinos - START Clinic
Ranjith Chandrasena - Chatham-Kent Health Alliance, Canada.
Larry J Klassen - Eden Mental Health Centre, Canada.
Irvin Epstein - START Clinic
Wende Wood - START Clinic
Martin A Katzman - NOSM University
Publication Details: Complementary therapies in medicine, Vol.36, pp.38-45
Publisher: Elsevier
Identifiers: 991013036324802368
Academic Unit: National Centre for Naturopathic Medicine
Language: English
Resource Type: Journal article

Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial

Files and links (2)

Metrics

UN Sustainable Development Goals (SDGs)

Abstract

Details

Southern Cross University Social media